推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 我國中醫(yī)藥發(fā)展歷史悠久,作為中華文化的先進代表,歷來受到國家高度重視,目前國家已經(jīng)把發(fā)展中醫(yī)藥上升到國家戰(zhàn)略高度,并出臺了一系列中醫(yī)藥扶持政策。中醫(yī)藥行業(yè)未來受益于政策扶持、中醫(yī)服務(wù)擴容、中醫(yī)藥創(chuàng)新以及海外發(fā)展等多項利好影響,有望迎來高速發(fā)展階段,并實現(xiàn)中醫(yī)藥十三五規(guī)劃目標,到2020年,中藥工業(yè)規(guī)模以上企業(yè)主營業(yè)務(wù)收入年復(fù)合增速15%。
中藥材質(zhì)量標準提升,規(guī)范化和規(guī)?；俏磥碲厔?/p>
中藥材種植作為中醫(yī)藥行業(yè)上游,關(guān)系到整個中醫(yī)藥行業(yè)的發(fā)展。十三五期間,中藥材行業(yè)將在中藥材產(chǎn)量穩(wěn)定增長、瀕危中藥材培育以及中藥材質(zhì)量提升等方面重點發(fā)展。我們認為,GAP基地建設(shè)以及中藥標準化項目將是未來質(zhì)量標準提升的重點。對于存在中藥材價格波動較大的問題,則需要從供需兩端協(xié)調(diào)解決。
中藥飲片明確受益于行業(yè)政策,有望迎來市場爆發(fā)
中藥飲片受益于中藥扶持政策,不納入集中采購、不取消加成以及不計入藥占比等政策使得中藥飲片面臨著前所未有的發(fā)展機遇。截止2015年底,中藥飲片市場規(guī)模約1700億元,占醫(yī)藥工業(yè)整體收入比重為6.32%,占比較小,仍有較大提升空間。同時受行業(yè)質(zhì)量標準提升影響,行業(yè)集中度有望繼續(xù)提升。
